Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D09LMK
|
||||
Former ID |
DIB001549
|
||||
Drug Name |
Lu-AA21004
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Mood disorder [ICD10:F30-F39] | Phase 3 | [532217] | ||
Company |
Lundbeck; takeda pharmaceuticals
|
||||
Structure |
Download2D MOL |
||||
Formula |
C18H22N2S
|
||||
Canonical SMILES |
c1(ccc(c(c1)C)Sc1ccccc1N1CCNCC1)C.Cl
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Sodium-dependent serotonin transporter | Target Info | Modulator | [531563], [532217], [532651] | |
KEGG Pathway | Serotonergic synapse | ||||
NetPath Pathway | TCR Signaling Pathway | ||||
References | |||||
Ref 531563 | A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol. 2012 Jun;15(5):589-600. | ||||
Ref 532217 | Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats. Pharmacol Biochem Behav. 2013 Apr;105:41-50. | ||||
Ref 532651 | 2013 FDA drug approvals. Nat Rev Drug Discov. 2014 Feb;13(2):85-9. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.